Tukysa is owned by Seagen.
Tukysa contains Tucatinib.
Tukysa has a total of 6 drug patents out of which 0 drug patents have expired.
Tukysa was authorised for market use on 17 April, 2020.
Tukysa is available in tablet;oral dosage forms.
Tukysa can be used as combination treatment of colorectal cancer including ras wild-type her2 (erbb2)-positive or -overexpressing unresectable or metastatic colorectal cancer, treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer.
Drug patent challenges can be filed against Tukysa from 2024-04-17.
The generics of Tukysa are possible to be released after 27 April, 2038.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7452895||SEAGEN||Quinazoline analogs as receptor tyrosine kinase inhibitors|| |
(1 year, 7 months from now)
|US8648087||SEAGEN||N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases|| |
(8 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9693989||SEAGEN||N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases|| |
(4 years from now)
|US9457093||SEAGEN||Solid dispersions of a ERB2 (HER2) inhibitor|| |
(9 years from now)
(10 years from now)
|US11207324||SEAGEN||Treatment of HER2 positive cancers|| |
(15 years from now)
|Orphan Drug Exclusivity (ODE)||Apr 17, 2027|
|New Chemical Entity Exclusivity (NCE)||Apr 17, 2025|
|New Indication (I)||Jan 19, 2026|
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: 2024-04-17
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer; Combination treatment of colorectal cancer including ras wild-type her2 (erbb2)-positive or -overexpressing unresectable or metastatic colorectal cancer
Korea, Republic of
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic